In the present work, we employed bioengineered OMVs displaying an anti-EGFR affibody on their surface toward triple-negative breast cancer cells and sought to explore whether the engineered OMVs can represent a novel, safe, and targeted biological nanoparticle against triple-negative breast cancer as one of the most challenging types of breast cancer in terms of chemotherapy strategy. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.